Skip to content
Live
Trending storyDeveloping

Isomorphic Labs completes funding

3 reports3 outlets47 minutes agoUpdate

The story so far

AI overview

Isomorphic Labs completes $5 billion Series C funding, led by Greenoaks and Sequoia Capital, with new investors like a16z joining, and Alphabet continuing its investment. The company will use the funds to advance the development of foundational simulation models, expand the scale of drug candidate projects, and build a global AI-driven biological engineering infrastructure. The company develops drug design technology based on DeepMind's AlphaFold model, which has achieved positive preclinical results in the fields of oncology and immunology, and has reached cooperation agreements with pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson. It previously raised $2.1 billion in Series B funding and completed a second round of $5 billion funding within six months.

AI-written from the reports · Updated 5 minutes ago

Coverage timeline

Follow the coverage to see every side of the story.

17 Nov
  1. TechCrunch · AI
    Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

    Isomorphic Labs announces completion of $5 billion Series C funding, aimed at advancing AI drug candidates into clinical trials; new funds will be used to develop a drug design engine and expand into more drug types, having previously raised $2.1 billion in Series B funding. The company develops drug design technology based on DeepMind's AlphaFold model and has achieved 'positive preclinical results' in the fields of oncology and immunology, collaborating with pharmaceutical companies like Eli Lilly, Novartis, and Johnson & Johnson.

  2. ITHome · AI
    Alphabet's drug AI company Isomorphic Labs completes $500 million C round financing

    Isomorphic Labs completes a total of $500 million in C round financing, led by Greenoaks and Sequoia Capital, with Alphabet continuing its investment; the company will use the funds to advance the development of fundamental simulation models, expand the scale of drug candidate projects, and build a global AI-driven biological engineering infrastructure.

Heat over time

Not enough data yet to draw a trend.